Foundry Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-84,325
| Closed | -$3.75M | – | 332 |
|
|
2022
Q2 | $3.75M | Hold |
84,325
| – | – | 0.23% | 121 |
|
|
2022
Q1 | $4.17M | Buy |
84,325
+22,660
| +37% | +$1.12M | 0.21% | 133 |
|
|
2021
Q4 | $3.14M | Sell |
61,665
-2,020
| -3% | -$103K | 0.11% | 205 |
|
|
2021
Q3 | $3.55M | Sell |
63,685
-2,900
| -4% | -$162K | 0.13% | 201 |
|
|
2021
Q2 | $2.85M | Sell |
66,585
-12,186
| -15% | -$522K | 0.1% | 232 |
|
|
2021
Q1 | $3.29M | Sell |
78,771
-2,905
| -4% | -$121K | 0.11% | 226 |
|
|
2020
Q4 | $3.8M | Buy |
81,676
+4,445
| +6% | +$207K | 0.15% | 194 |
|
|
2020
Q3 | $3.28M | Buy |
77,231
+2,158
| +3% | +$91.7K | 0.16% | 182 |
|
|
2020
Q2 | $3.6M | Sell |
75,073
-9,504
| -11% | -$456K | 0.18% | 168 |
|
|
2020
Q1 | $3.89M | Buy |
84,577
+14,220
| +20% | +$654K | 0.22% | 141 |
|
|
2019
Q4 | $4.23M | Sell |
70,357
-5,803
| -8% | -$349K | 0.16% | 189 |
|
|
2019
Q3 | $4.31M | Buy |
76,160
+2,775
| +4% | +$157K | 0.18% | 185 |
|
|
2019
Q2 | $4.09M | Buy |
73,385
+65,785
| +866% | +$3.66M | 0.16% | 192 |
|
|
2019
Q1 | $384K | Hold |
7,600
| – | – | 0.02% | 358 |
|
|
2018
Q4 | $306K | Buy |
7,600
+2,350
| +45% | +$94.6K | 0.01% | 368 |
|
|
2018
Q3 | $364K | Sell |
5,250
-415
| -7% | -$28.8K | 0.01% | 363 |
|
|
2018
Q2 | $429K | Hold |
5,665
| – | – | 0.02% | 352 |
|
|
2018
Q1 | $298K | Sell |
5,665
-1,650
| -23% | -$86.8K | 0.01% | 375 |
|
|
2017
Q4 | $391K | Buy |
7,315
+3,565
| +95% | +$191K | 0.02% | 349 |
|
|
2017
Q3 | $224K | Buy |
+3,750
| New | +$224K | 0.01% | 383 |
|